Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amibegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 12/20 | 0.91 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amibegron SCHEMBL8765764 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL2052478 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3898164 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL29373533 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3824162 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL6931932 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL9006793 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3908665 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL9317343 | 0.99 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3897916 | 0.99 | ADRB3 (0.89) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966276-B1 | USE OF BETA-3 ADRENERGIC RECEPTOR AGONISTS FOR PREPARING WOUND-HEALING PHARMACEUTICALS | SANOFI SYNTHELABO (FR) | 2003-12-10 | — | — | EP | claimed |
| EP-0556880-A2 | Medical use for atypical beta-adrenoceptor agonists | GLAXO GROUP LIMITED (GB) | 1993-08-25 | — | — | EP | claimed |
| EP-0211721-B1 | PHENYLETHANOL AMINOTETRALINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI S.A. (FR) | 1989-10-04 | — | — | EP | claimed |
| EP-0211721-A1 | Phenylethanol aminotetralines, process for their preparation and pharmaceutical compositions containing them | SANOFI S.A. (FR) | 1987-02-25 | — | — | EP | claimed |
| EP-3463312-A1 | DOSING REGIMENS FOR BETA-3 ADRENOCEPTOR AGONISTS AND ANTI-MUSCARINIC AGENTS FOR THE TREATMENT AND PREVENTION OF LOWER URINARY TRACT SYMPTOMS AND OVERACTIVE BLADDER | Velicept Therapeutics, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017210696-A1 | DOSING REGIMENS FOR BETA-3 ADRENOCEPTOR AGONISTS AND ANTI-MUSCARINIC AGENTS FOR THE TREATMENT AND PREVENTION OF LOWER URINARY TRACT SYMPTOMS AND OVERACTIVE BLADDER | VELICEPT THERAPEUTICS, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| EP-1795194-A2 | Use of an antagonist of CB1 receivers associated with a beta3-agonist for preparing medication to be used for treating appetence | Sanofi-Aventis (FR) | 2007-06-13 | — | — | EP | disclosed |
| US-20050026986-A1 | Use of central cannabinoid receptor antagonists for the preparation of drugs | SANOFI-AVENTIS (FR) | 2005-02-03 | — | — | US | disclosed |
| US-6703422-B2 | FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISEASE, DYSLIPIDEMIA; DYSLIPOPROTEINEMIA; DISORDER OF GLUCOSE METABOLISM; ALZHEIMER'S DISEASE; SYNDROME X; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ASSOCIATED DISORDER | ESPERION THERAPEUTICS, INC. | 2004-03-09 | — | — | US | disclosed |
| US-6696486-B1 | GASTROINTESTINAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-02-24 | — | — | US | disclosed |
| EP-0966276-B1 | USE OF BETA-3 ADRENERGIC RECEPTOR AGONISTS FOR PREPARING WOUND-HEALING PHARMACEUTICALS | SANOFI SYNTHELABO (FR) | 2003-12-10 | — | — | EP | disclosed |
| US-20020128302-A1 | Use of central cannabinoid receptor antagonists for the preparation of drugs | MARUANI JEANNE (FR) | 2002-09-12 | — | — | US | disclosed |
| US-5198586-A | Process for the preparation of phenylethanolaminotetralins | SANOFI (FR) | 1993-03-30 | — | — | US | disclosed |
| US-5159103-A | 2-amino-7-hydroxytetraline ethers | SANOFI (FR) | 1992-10-27 | — | — | US | disclosed |
| EP-0303545-B1 | PROCESS FOR THE PREPARATION OF PHENYLETHANOLAMINOTETRALINES | ELF SANOFI (FR) | 1992-06-17 | — | — | EP | disclosed |
| US-5041606-A | Process for the O-alkylation of N-(hydroxy)aralkylphenylethanolamines | SANOFI | 1991-08-20 | — | — | US | disclosed |
| EP-0383686-A1 | 2-Amino-7-hydroxytetraline carboxyalkyl ethers | ELF SANOFI (FR) | 1990-08-22 | — | — | EP | disclosed |
| US-4927955-A | Process for the O-alkylation of N-(hydroxy)aralkylphenylethanolamines | SANOFI (FR) | 1990-05-22 | — | — | US | disclosed |
| EP-0303546-A2 | O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines | SANOFI (FR) | 1989-02-15 | — | — | EP | disclosed |
| EP-0303545-A2 | Process for the preparation of phenylethanolaminotetralines | ELF SANOFI (FR) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026986-A1 | Use of central cannabinoid receptor antagonists for the preparation of drugs | CNR1, CNR2, ADRB3 | ADRB3 3/4885ADRB1 4/4885 |
| US-20020128302-A1 | Use of central cannabinoid receptor antagonists for the preparation of drugs | CNR1, CNR2, GPR119 | ADRB3 4/4885ADRB1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.